TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis

Cytokine

Volumn 46, Issue 2, 2009, Pages 222-227

  Olsen, Trine ^a   Goll, Rasmus ^a   Cui, Guanglin ^a   Christiansen, Ingrid ^a   Florholmen, Jon ^b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Cytokines; Inflammatory bowel disease; Quantitative real time PCR

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 4; MESALAZINE; MESSENGER RNA; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL TRIAL; COLITIS; COLON MUCOSA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; GASTROINTESTINAL ENDOSCOPY; GENE EXPRESSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RECTUM MUCOSA; REMISSION; STEROID THERAPY; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; COLON; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECTUM; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 65049087340     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.02.001     Document Type: Article

References (33)

1. Sartor R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3 7 (2006) 390-407
2. Dionne S., Hiscott J., D'Agata I., Duhaime A., and Seidman E.G. Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies. Dig Dis Sci 42 7 (1997) 1557-1566
3. Stallmach A., Giese T., Schmidt C., Ludwig B., Mueller-Molaian I., and Meuer S.C. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int J Colorectal Dis 19 4 (2004) 308-315
4. McCormack G., Moriarty D., O'Donoghue D.P., McCormick P.A., Sheahan K., and Baird A.W. Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res 50 10 (2001) 491-495
5. Melmed G.Y., and Abreu M.T. New insights into the pathogenesis of inflammatory bowel disease. Curr Gastroenterol Rep 6 6 (2004) 474-481
6. Bouma G., and Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3 7 (2003) 521-533
7. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157 3 (1996) 1261-1270
8. Heller F., Florian P., Bojarski C., Richter J., Christ M., Hillenbrand B., et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129 2 (2005) 550-564
9. Olsen T., Goll R., Cui G., Husebekk A., Vonen B., Birketvedt G.S., et al. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol 42 11 (2007) 1312-1320
10. Akazawa A., Sakaida I., Higaki S., Kubo Y., Uchida K., and Okita K. Increased expression of tumor necrosis factor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase. J Gastroenterol 37 5 (2002) 345-353
11. Casellas F., Papo M., Guarner F., Antolin M., Armengol J.R., and Malagelada J.R. Intraluminal colonic release of immunoreactive tumour necrosis factor in chronic ulcerative colitis. Clin Sci (Lond) 87 4 (1994) 453-458
12. Jarnerot G., Hertervig E., Friis-Liby I., Blomquist L., Karlen P., Granno C., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 7 (2005) 1805-1811
13. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 23 (2005) 2462-2476
14. Ferrante M., Vermeire S., Katsanos K.H., Noman M., Van A.G., Schnitzler F., et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 13 2 (2007) 123-128
15. Sands B.E. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 126 6 (2004) 1518-1532
16. Marteau P., Probert C.S., Lindgren S., Gassul M., Tan T.G., Dignass A., et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 54 7 (2005) 960-965
17. Sutherland L.R., Martin F., Greer S., Robinson M., Greenberger N., Saibil F., et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92 6 (1987) 1894-1898
18. Su C., Lewis J.D., Goldberg B., Brensinger C., and Lichtenstein G.R. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 132 2 (2007) 516-526
19. Cui G., Olsen T., Christiansen I., Vonen B., Florholmen J., and Goll R. Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: an approach to optimize procedures for clinical use. Scand J Clin Lab Invest 66 3 (2006) 249-259
20. Goll R., Olsen T., Cui G., and Florholmen J. Evaluation of absolute quantitation by nonlinear regression in probe-based real-time PCR. BMC Bioinformatics 7 (2006) 107
21. Cui G., Goll R., Olsen T., Steigen S.E., Husebekk A., Vonen B., et al. Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum. Cancer Immunol Immunother 66 3 (2006) 249-259
22. Nielsen O.H., Gionchetti P., Ainsworth M., Vainer B., Campieri M., Borregaard N., et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 94 10 (1999) 2923-2928
23. Guimbaud R., Bertrand V., Chauvelot-Moachon L., Quartier G., Vidon N., Giroud J.P., et al. Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis. Am J Gastroenterol 93 12 (1998) 2397-2404
24. Tsukada Y., Nakamura T., Iimura M., Iizuka B.E., and Hayashi N. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol 97 11 (2002) 2820-2828
25. Vermeire S., Louis E., Carbonez A., Van A.G., Noman M., Belaiche J., et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 97 9 (2002) 2357-2363
26. Louis E., Vermeire S., Rutgeerts P., De V.M., Van G.A., Pescatore P., et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 37 7 (2002) 818-824
27. Parsi M.A., Achkar J.P., Richardson S., Katz J., Hammel J.P., Lashner B.A., et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 123 3 (2002) 707-713
28. Schmidt C., Giese T., Hermann E., Zeuzem S., Meuer S.C., and Stallmach A. Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy. Inflamm Bowel Dis 13 1 (2007) 65-70
29. Martinez-Borra J., Lopez-Larrea C., Gonzalez S., Fuentes D., Dieguez A., Deschamps E.M., et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 97 9 (2002) 2350-2356
30. Bustin S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25 2 (2000) 169-193
31. Joelle T., Guanglin C., Goll R., Nestegaard O., Kvamme J., Paulssen E., et al. Anti-TNF alpha (infliximab) treatment suppresses tissue TNF-alpha mRNA expression and induces clinical remission in ulceratvie colitis. Gut Suppl 53 (2004) A310
32. Van A.G., Vermeire S., and Rutgeerts P. Optimizing treatment of inflammatory bowel diseases with biologic agents. Curr Gastroenterol Rep 10 6 (2008) 591-596
33. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 9317 (2002) 1541-1549